ADispell research has revealed a novel mechanism that explains the onset of Alzheimer's Disease and has discovered lead compounds that interact with that mechanism in a way that has potential to halt disease advancement. ADispell is working with this novel discovery, licensed from Cornell University, that identical binding sites exist on the ion channels of the neurons in the brain and on the amyloid peptide, raising the possibility that one drug might affect the two major mechanisms believed to be involved in Alzheimer's. This unique approach has led to the identification of two lead compounds that have been tested successfully for both sites in vitro. ADispell now is planning to perform in vivo testing.